Open AccessFluticasone propionate in clinically suspected asthma patients with negative methacholine challenge test
Author(s) -
Peiman Soheil,
Abtahi Hamidreza,
Akhondzadeh Shahin,
Safavi Enayat,
Moin Mostafa,
Rahimi Foroushani Abbas
Publication year - 2017
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.12353
Subject(s) - medicine , fluticasone propionate , bronchodilator , asthma , methacholine , wheeze , inhaler , fluticasone , anesthesia , respiratory disease , lung
Abstract Introduction Despite reports of response to steroid inhaler in some clinically suspected asthma patients with negative methacholine challenge test (CSA/MCT−), treatment in these patients has not been prospectively studied. Objective We studied the role of a 12 week high dose inhaled fluticasone trial in CSA/MCT− patients. Methods After a 2 week run‐in period, CSA/MCT−patients were treated with 12 weeks of Fluticasone propionate 1000 µg/day. The Asthma Control Test (ACT), numeric cough score (NCS) and bronchodilator use were compared with their pretreatment values. Results Thirty‐four of 42 CSA/MCT−patients completed the study. Mean pretreatment ACT score (pACT) was significantly increased after treatment (14.7 ± 3.37 to 20.9 ± 3.1, P < 0.001). Posttreatment values of daytime (1.0 ± 1.0) and night‐time (0.6 ± 0.9) NCS decreased compared to their pretreatment values (2.8 ± 1.1 and 1.9 ± 1.3, respectively; P < 0.001). ACT score change (ΔACT) were significantly greater in those with pACT < 15 than in those ≥15 ( P < 0.001) . Fifteen of 21 patients with ΔACT > 5 did not need to use bronchodilator for their symptom relief. Wheeze disappeared in all six patients with ΔACT > 5 after the trial. Six months after the study, steroid inhaler continued to be used by 72.2% of patients. Conclusion A significant portion of CSA/MCT− (especially those with pretreatment ACT score <15) respond to high dose fluticasone inhaler in terms of symptoms relief, disappearance of wheeze and need to bronchodilator use. ΔACT could not be predicted with any individual symptoms or signs before MCT, % FEV1 decline or symptoms during MCT and exhaled nitric oxide.